RNAC (Cartesian Therapeutics) Market Value to Book Value Ratio

Cartesian Therapeutics management specializes in developing safe, next-generation cell therapies. Currently, pricing power depends on clinical trial outcomes, which will enable the company to demand higher reimbursement rates from insurers in the future. The price action history on GURU.Markets, where the indicator stands at -1.52, confirms its status as an innovator utilizing mRNA for genome-modification-free therapy.

Selecta Biosciences Inc. (RNAC): Capitalization to Book Value Ratio from 02/21/2024 to 10/27/2026

Financial and market metric breakdowns for Selecta Biosciences (RNAC)

- price and consensus price forecast:

Stock Price Cartesian Therapeutics|RNAC - Consensus Target

- market capitalization data:

Market Value Cartesian Therapeutics Inc|RNAC - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Cartesian Therapeutics|RNAC - Accounting Capitalization|Market Capitalization to Book Value Ratio selectabio.com|RNAC - Cumulative Company Assets

- debt and liquidity data:

Debt to Equity Cartesian Therapeutics|RNAC - Long-Term Liabilities to Capital|Short-Term Debt to Equity Cartesian Therapeutics Inc|RNAC - Company Debts|Debt to Book Capitalization Ratio Cartesian Therapeutics Inc

Fundamental valuation:Cartesian Therapeutics

Investors are assessing the resilience of Cartesian Therapeutics (RNAC) through the price-to-book ratio, which measures the market valuation premium over actual net assets. By analyzing the history of the market value exceeding the book value, one can understand the extent to which the market currently prices in the future impact of bioreactor robotization and AI-driven control of RNA drug synthesis, which minimize operational risks.

Competitor analysis

LEGN (Legend Biotech) - Market Capitalization to Book Value Ratio|SANA (sana.com) - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio AUTL (Autolus Therapeutics plc)|Market-to-Book Ratio ALLO|Market Value to Book Value Ratio Cellectis S.A. CLLS|Capitalization to Book Value Ratio Caribou Biosciences, Inc (CRBU)|Instil Bio, Inc. - Market Capitalization to Book Value Ratio|Genenta Science SpA - Market Cap to Net Assets Ratio|IPSC (Century Therapeutics Inc) - Market Value to Book Value Ratio|JSPR: Market-to-Book Ratio|sentibio.com (SNTI) - Market Value to Book Value Ratio|ADAP (Adaptimmune Therapeutics) - Market Value to Book Value Ratio|Market Value to Book Value Ratio CERO (CERo Therapeutics Holdings, Inc.)|Market-to-Book Ratio Alaunos|ACHL: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio CARGO Therapeutics Inc. CRGX|PSTX: Market Cap to Net Assets Ratio|TSVT - Market-to-Book Ratio|Market Cap to Net Assets Ratio Gracell Biotechnologies (GRCL)